Trial Profile

Phase II Multicentered Study of Exemestane and Lapatinib in Advanced Hormone-responsive Breast Cancer.

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exemestane (Primary) ; Lapatinib (Primary)
Indications Advanced breast cancer
Focus Adverse reactions; Biomarker; Therapeutic Use
Acronyms ELBA

Most Recent Events

21 Nov 2009 Planned initiation date changed from 1 Oct 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
09 Nov 2009 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com